Provectus Biopharmaceuticals I - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PVCT Over the counter 8731 https://www.provectusbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Provectus Biopharmaceuticals I

Provectus: Q2 Earnings Snapshot - Aug 13th, 2024 5:27 pm
Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders - Jun 13th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting - May 21st, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting - May 14th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia) - May 2nd, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers - Apr 18th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation - Apr 16th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting - Apr 11th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium - Mar 27th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines - Mar 12th, 2024 12:00 pm
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting - Mar 7th, 2024 1:00 pm
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting - Feb 29th, 2024 1:00 pm
Provectus Biopharmaceuticals, Inc. (PNK:PVCT) Q1 2024 Earnings Call Transcript - Feb 23rd, 2024 4:30 pm
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call - Feb 15th, 2024 1:00 pm
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services - Feb 14th, 2024 1:00 pm
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant - Dec 18th, 2023 1:00 pm
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Advanced Cutaneous Melanoma - Nov 15th, 2023 2:00 pm
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma - Nov 13th, 2023 1:00 pm
Provectus Biopharmaceuticals Announces Presentation of Preclinical PV-10 Vaccine Adjuvant Data at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting - Nov 6th, 2023 1:00 pm